Status:
RECRUITING
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Lead Sponsor:
Catherine Bollard
Collaborating Sponsors:
Children's National Research Institute
Johns Hopkins University
Conditions:
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Eligibility:
All Genders
6-80 years
Phase:
PHASE1
Brief Summary
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high...
Detailed Description
Patients with evidence of high-risk or relapsed or persistent hematopoietic malignancies (for example but not limited to: acute myeloid leukemia and myelodysplastic syndrome (MDS)) will be eligible fo...
Eligibility Criteria
Inclusion
- Recipient Inclusion Criteria to Enter Protocol:
- Aged 6 months to 80 years.
- Anticipated myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant.
- Patients with high risk AML and MDS who have received or will receive an allo-HSCT and have not had hematologic relapse of disease.
- Karnofsky/Lansky score of ≥ 50.
- Agree to use contraceptive measures during study protocol participation (when age appropriate).
- Patient or parent/guardian capable of providing informed consent.
- T cell chimerism \> 94% if collected from recipient of allo-HSCT
- Recipient Exclusion Criteria to Enter Protocol:
- Patients with uncontrolled infections.
- Current evidence of GVHD \> grade 2 or bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis.
- Pregnancy (female of childbearing potential).
- Recipient Inclusion Criteria for TAA-T Administration:
- Patients with high risk AML and MDS who have received an allo-HSCT and have not had hematologic relapse of disease.
- Steroids less than 0.5 mg/kg/day prednisone or equivalent in the context of no escalation of treatment within the preceding 2 weeks
- Karnofsky/Lansky score of ≥ 50.
- Bilirubin \< 2.5 mg/dL, AST/ALT \<5x upper limit of normal, Serum creatinine \< 1.0 or 2x the upper limit of normal (whichever is higher).
- Pulse oximetry of \> 90% on room air.
- Absolute neutrophil count \> 250/ µL (may be supported with Granulocyte colony-stimulating factor (GCSF)).
- Agree to use contraceptive measures during study protocol participation (when age appropriate).
- Patient or parent/guardian capable of providing informed consent.
- LVEF \> 50% or LVSF \> 27% (performed within the last 6 months) if history of TBI \>500 cGy for arm A and B.
- Total chimerism \> 50%; or if cancer cells preclude this, donor T cell chimerism \> 50% (performed within the last 6 months).
- Recipient Exclusion Criteria for TAA-T Administration:
- Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies within 28 days prior to TAA-T infusion.
- No investigational therapies (under IND, not extensively studied in the current clinical context) within 28 days prior to TAA-T infusion.
- Uncontrolled infections.
- Active Bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis.
- Active acute GVHD or chronic GVHD requiring escalation of treatment within preceding 2 weeks of any grade is exclusion for Arm C patients.
- Pregnancy or lactating (female of childbearing potential).
- Patients who have or will be receiving 2nd allogeneic HSCT
- Donor
- Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have undergone eligibility evaluation as per FDA regulations outlined in 21 CFR 1271 subpart C. If a donor has been chosen for the transplant based on urgent medical need, that same donor will also be used for TAA-T generation provided that there are no new reasons for ineligibility since the transplant donor evaluation.
- Aged 6 months to 80 years.
- Donor or guardian of pediatric capable of providing informed consent.
- Donor must have completed infectious Disease (ID) testing up to 7 days before or after the collection of blood from the donor (related or unrelated) for TAA-T manufacturing. The following tests will be performed:
- HBsAg
- HB Core antibody
- HIV1/2 NAT
- Syphilis (T. Pallidum IgG)
- HTLV I/II
- CMV total
- HBV/HCV NAT
- West Nile Virus NAT.
- Cruz (Chagas) antibody
- Hepatitis C
- Female donors of childbearing age must have a negative pregnancy test within 7 days of blood collection for TAA-T manufacturing.
- Donor
Exclusion
- Donation of cells would pose a physical or psychological risk to the donor.
- Female donors of childbearing age who are known to be pregnant.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 28 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02203903
Start Date
January 1 2015
End Date
June 28 2027
Last Update
May 31 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens National Medical Center
Washington D.C., District of Columbia, United States, 20010
2
Tania Jain, MD
Baltimore, Maryland, United States, 21287